The MedicalXpress report frames the Bundibugyo outbreak as a standard WHO emergency declaration with 336 cases and 88 deaths, yet it underplays the structural weaknesses that have repeatedly allowed Ebola to breach borders. Past observational studies, including a 2016 Lancet analysis of the 2014–2016 West Africa epidemic (n>28,000 cases, retrospective cohort design with no RCT component and minimal industry conflicts), documented how delayed contact tracing across porous frontiers enabled exponential growth. Current figures from DRC and Uganda already show transmission reaching Kampala, echoing the same pattern. Bundibugyo’s lack of licensed vaccines—unlike Zaire-strain products Ervebo and Zabdeno—stems from limited pre-clinical animal data only, leaving health systems without the ring-vaccination tools that curbed prior Zaire outbreaks. Peer-reviewed modeling from the 2007 Ugandan Bundibugyo event (small observational series, n<100) indicated lower case fatality but higher undetected spread due to milder initial symptoms. The original coverage reduces these dynamics to travel advisories; the deeper lesson is that fragmented national surveillance, rather than viral novelty, drives international risk.